p15 promoter methylation - A novel prognostic marker in glioblastoma patients

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1743-1748

  Wemmert, Silke ^a   Bettscheider, Marc ^a   Alt, Simone ^a   Ketter, Ralf ^a   Kammers, Kai ^b   Feiden, Wolfgang ^a   Steudel, Wolf Ingo ^a   Rahnenführer, Jörg ^b   Urbschat, Steffi ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

Glioblastoma; Methylation; MGMT; p15; Prognosis

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P14; PROTEIN P14 ARF; PROTEIN P15; PROTEIN P16; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE REPRESSION; GLIOBLASTOMA; HUMAN; KAPOSI SARCOMA; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; RETROSPECTIVE STUDY;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 67649442519     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000305     Document Type: Article

References (38)

1. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: WHO Classification of Tumours of the Central Nervous System. 4th edition. International Agency for Research on Cancer, Lyon, 2007.
2. Burger PC and Green SB: Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 59: 1617-1625, 1987.
3. Kreth FW, Warnke PC, Scheremet R and Ostertag CB: Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 78: 762-766, 1993.
4. Lacroix M, Abi-Said D, Fourney DR, et al: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
5. Stummer W, Reulen HJ, Meinel T, et al: Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 62: 564-576, 2008.
6. Jen J, Harper JW, Bigner SH, et al: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
7. Schmidt EE, Ichimura K, Reifenberger G and Collins VP: CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 54: 6321-6324, 1994.
8. Simon M, Köster G, Menon AG and Schramm J: Functional evidence for a role of combined CDKN2A[p16/p14(arf))]/CDKN2B (p15) gene inactivation in malignant gliomas. Acta Neuropathol 98: 444-452, 1999.
9. Rasheed A, Herndon JE, Stenzel TT, et al: Molecular markers of prognosis in astrocytic tumors. Cancer 94: 2688-2697, 2002.
10. Gil J and Peters G: Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667-677, 2006.
11. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55: 4833-4836, 1995.
12. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13: 1065-1072, 1996.
13. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A and Collins VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 60: 417-424, 2000.
14. Fulci G, Labuhn M, Maier D, et al: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822, 2000.
15. Kamiryo T, Tada K, Shiraishi S, et al: Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg 96: 815-822, 2002.
16. Wemmert S, Ketter R, Rahnenführer J, et al: Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 7: 883-893, 2005.
17. ARF in radio-and chemosensitivity of malignant gliomas. Oncol Rep 16: 127-132, 2006.
18. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
19. INK4B1. Cancer Res 56: 722-727, 1996.
20. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
21. Uhlmann K, Rohde K, Zeller C, et al: Distinct methylation profiles of glioma subtypes. Int J Cancer 106: 52-59, 2003.
22. INK4B gene in myelodysplastic syndromes. Blood 90: 1403-1409, 1997.
23. Kudoh K, Ichikawa Y, Yoshida S, et al: Inactivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 99: 579-582, 2002.
24. ARF gene hypermethylation in human colon cancer. Pathol Res Pract 202: 415-424, 2006.
25. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
26. Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
27. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
28. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 113: 581-587, 2005.
29. Blanc JL, Wager M, Guilhot J, et al: Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68: 275-283, 2004.
30. Crinière E, Kaloshi G, Laigle-Donadey F, et al: MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83: 173-179, 2007.
31. Sato F, Harpaz N, Shibata D, et al: Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62: 1148-1151, 2002.
32. 6-methylguanin methyltransferase (MGMT) promotor methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008.
33. Loeper S, Romeike BF, Heckmann N, et al: Frequent mitotic errors in tumor cells of genetically micro-heterogeneous glioblastomas. Cytogenet Cell Genet 94: 1-8, 2001.
34. Jung V, Romeike BF, Henn W, Feiden W, Moringlane JR, Zang KD and Urbschat S: Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells. J Neuropathol Exp Neurol 58: 993-999, 1999.
35. Komata T, Kanzawa T, Takeuchi H, Germano IM, Schreiber M, Kondo Y and Kondo S: Antitumor effect of cyclin-dependent kinase inhibitors [p16(INK4A), p18(INK4C), p19(INK4D)]. p21 [WAF1(CIP1) and p27 (KIP1)] on malignant glioma cells. Br J Cancer 88: 1277-1280, 2003.
36. Inoue R, Moghaddam KA, Ranasinghe M, Saeki Y, Chiocca EA and Wade-Martins R: Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spiced gene expression and growth suppression in glioma cells. Gene Ther 11: 1195-1204, 2004.
37. INK4a cDNA inhibits C6 glioma formation in Wistar rats. Cancer Cell Int 2: 1-9, 2002.
38. 6-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17: 5-10, 2007.